Mycophenolate vs Cyclophosphamide in SLE Nephritis
EBM, Landmark Research
Age-Adjusted D-dimer Cutoff Levels to Rule Out Pulmonary Embolism: The ADJUST-PE Study
EBM, Journal Club
What d-dimer threshold do you use to determine if a patient potentially has a pulmonary embolism? Do you adjust it according to the patient's age? Is that even valid? This prospective validation study helps answer this question: Does adjusting the…
Optimal Medical Therapy with or without PCI for Stable Coronary Disease (COURAGE Trial)
EBM, Landmark Research
Role of Echocardiography in Evaluation of Patient with S aureus Bacteremia
EBM, Landmark Research
Fluoxetine for Motor Recovery After Acute Ischaemic Stroke (FLAME): A Randomised Placebo-controlled Trial
EBM, Journal Club
Clinical Question: Can adding fluoxetine to standard therapy for ischemic stroke improve recovery from motor deficits?
Einstein Choice: Rivaroxaban or Aspirin for Extended Treatment of Venous Thromboembolism
EBM, Journal Club
Clinical Question In patients who would benefit from continued anti-coagulation is treatment dose rivaroxaban vs thromboprophylactic dose as effective as aspirin for prevention of recurrent thromboembolism? Bottom Line Rivaroxaban at both treatment dose (20mg) and a thromboprophylactic dose (10mg), was…
PESIT Trial
EBM, Journal Club
Thank you Dr. Noah Duncan for an excellent overview of the PESIT trial (Prevalence of Pulmonary Embolism among Patients Hospitalized for Syncope) Conclusions of the study: Pulmonary embolism was identified in nearly one of every 6 patients hospitalized for a…